Chengdu Better Denuo Pharmaceutical Co., Ltd.

Primary study objective: This study used spironolactone oral suspension (118ml: 0.59g) produced by Chengdu Beitedenuo Pharmaceutical Co., Ltd. as the test preparation and spironolactone oral suspension (118ml: 0.59g (25mg/5mL, 118mL/bottle), trade name: CAROSPIR®) held by Cmp Development Llc as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation under postprandial conditions. Secondary study objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

To compare the differences in absorption extent and rate of ursodeoxycholic acid oral suspension (specification: 250 mL: 12.5 g) produced by Chengdu Betedenuo Pharmaceutical Co., Ltd. and ursodeoxycholic acid oral suspension (specification: 250 mL: 12.5 g, trade name: Ursofalk®) certified by Dr. Falk Pharma GmbH in healthy Chinese adult subjects under fasting and fed conditions, to evaluate the bioequivalence of the two oral preparations under fasting and fed conditions, and to evaluate the safety of ursodeoxycholic acid oral suspension (specification: 250 mL: 12.5 g) produced by Chengdu Betedenuo Pharmaceutical Co., Ltd.

To compare the differences in absorption extent and rate of ursodeoxycholic acid oral suspension (specification: 250 mL: 12.5 g) produced by Chengdu Betedenuo Pharmaceutical Co., Ltd. and ursodeoxycholic acid oral suspension (specification: 250 mL: 12.5 g, trade name: Ursofalk®) certified by Dr. Falk Pharma GmbH in healthy Chinese adult subjects under fasting and fed conditions, to evaluate the bioequivalence of the two oral preparations under fasting and fed conditions, and to evaluate the safety of ursodeoxycholic acid oral suspension (specification: 250 mL: 12.5 g) produced by Chengdu Betedenuo Pharmaceutical Co., Ltd.